- The study addressed the unclear effects of heparin dosing and activated clotting time (ACT) monitoring on postoperative outcomes after lower extremity bypass.
- Researchers analyzed 10,040 lower extremity bypass patients from 34 hospitals using a Bayesian random-effects multivariable logistic regression model.
- Heparin dose was not associated with thrombosis (OR 0.88, 95% CI 0.70-1.11) or bleeding (OR 0.99, 95% CI 0.76-1.29).
- The authors concluded that heparin dose, intraoperative ACT monitoring, and achieving an ACT >250 were not associated with assessed outcomes.
- Administering adequate heparin without ACT monitoring may provide equivalent outcomes, potentially reducing costs and logistical challenges.
Rethinking Anticoagulation Monitoring in Lower Extremity Bypass
Lower extremity bypass (LEB) is a critical intervention for advanced peripheral arterial disease, designed to restore perfusion and prevent major amputation [1]. A central component of the procedure is intraoperative anticoagulation to maintain graft patency, yet this creates a delicate balance against the risk of postoperative bleeding [2, 3, 4, 5]. While heparin is standard, the optimal method for monitoring its effect, particularly the utility of measuring activated clotting time (ACT), has been a subject of considerable clinical debate and practice variation [6]. A recent large-scale study offers new data that may help clarify the value of these long-standing monitoring practices for clinicians.
Understanding the Clinical Question and Study Design
While anticoagulation is essential for preventing thrombosis after vascular surgery, the specific impact of heparin dosing strategies and ACT monitoring on postoperative outcomes has remained poorly defined. To address this gap, investigators analyzed data from a statewide collaborative to evaluate the real-world effects of these practices. The study examined rates of postoperative bleeding, arterial or graft thrombosis, major amputation, readmission, and death within 30 days of LEB. To analyze this complex dataset, the researchers employed a Bayesian random-effects multivariable logistic regression model. This statistical approach is particularly well-suited for this type of clinical data because it can account for the fact that patient outcomes may be clustered by individual surgeons or hospital-wide protocols, thus isolating the true effects of heparin and ACT monitoring from confounding practice patterns.
Patient Cohort and Baseline Outcomes
The analysis drew upon a large and diverse cohort, comprising 10,040 patients who underwent LEB at 34 different hospitals. This substantial sample size provides significant statistical power to the study's conclusions. Within this group, key 30-day adverse events were recorded: 215 patients (2.1%) developed predischarge arterial or graft thrombosis, 167 (1.7%) had postoperative bleeding, 950 (9.5%) required a major amputation, 1,132 (11.3%) were readmitted, and 51 (0.5%) died. A critical finding was the profound inconsistency in clinical practice regarding anticoagulation monitoring. The use of ACT monitoring varied dramatically between institutions, from a low of 12% of cases to a high of 100%. Overall, just under half of the patients, 4,921 (49.1%), had their ACT monitored, highlighting a lack of consensus on the utility of this measurement in routine practice.
Lack of Association Between Heparin Parameters and Outcomes
Contrary to long-held assumptions, the study's primary analysis found no significant link between the amount of heparin administered and key adverse events. Specifically, heparin dose was not associated with post-operative thrombosis (Odds Ratio [OR] 0.88, 95% Credible Interval [CI] 0.70-1.11), 30-day amputation (OR 0.93, 95% CI 0.81-1.05), or postoperative bleeding (OR 0.99, 95% CI 0.76-1.29). The credible interval, which is the Bayesian analog to a confidence interval, crossed 1.0 for all these outcomes, indicating a lack of a statistically significant effect. Furthermore, the investigation challenged the value of a common monitoring target, revealing that achieving an ACT greater than 250 seconds was not associated with postoperative bleeding, thrombosis, amputation, readmission, or mortality. To probe this further, the authors performed receiver operating characteristic (ROC) curve analysis, a method used to assess how well a test can distinguish between two groups (e.g., patients who will bleed versus those who will not). This analysis confirmed that no specific ACT value served as a reliable predictive cutoff for any of the assessed outcomes.
Protamine's Role and Clinical Implications
Although the study largely found no benefit from common heparin monitoring strategies, it did identify a protective factor. The administration of protamine for heparin reversal was associated with a significant reduction in post-operative bleeding, with an odds ratio of 0.51 (95% Credible Interval 0.36-0.72). This suggests that while monitoring heparin's effect may be of limited value, managing its reversal is clinically important. The study's main conclusions, however, center on the lack of association between intraoperative anticoagulation parameters and patient outcomes. The findings demonstrate that heparin dose, the practice of ACT monitoring itself, and the achievement of a specific ACT target (greater than 250 seconds) were not linked to differences in thrombosis, bleeding, amputation, readmission, or mortality. From a clinical practice standpoint, these results suggest that administering adequate heparin doses without routine ACT monitoring may provide equivalent patient outcomes, potentially simplifying the surgical workflow and reducing the costs and logistical burdens associated with intraoperative testing.
References
1. Aboyans V, Ricco J, Bartelink M, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal. 2017. doi:10.1093/eurheartj/ehx095
2. Junqueira DR, Zorzela L, Golder S, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ. 2023. doi:10.1136/bmj-2022-073725
3. Junqueira DR, Zorzela L, Golder S, et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials. Journal of Clinical Epidemiology. 2023. doi:10.1016/j.jclinepi.2023.04.005
4. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Advances. 2019. doi:10.1182/bloodadvances.2019000975
5. Rossaint R, Afshari A, Bouillon B, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Critical Care. 2023. doi:10.1186/s13054-023-04327-7
6. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances. 2018. doi:10.1182/bloodadvances.2018024489